31 March 2026
31 March 2026
The integration supports treatment decisions across cancer care stages and helps reduce administrative tasks for clinicians.
The PREVAiLS study will be conducted at up to 60 ALS centres throughout 13 countries.
The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.
The algorithm integrates with EHR systems and ECG platforms, operating within the health system without external data transfer.
The PREVAiLS study will be conducted at up to 60 ALS centres throughout 13 countries.
The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.
The algorithm integrates with EHR systems and ECG platforms, operating within the health system without external data transfer.
The PREVAiLS study will be conducted at up to 60 ALS centres throughout 13 countries.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
